Alphamab Oncology’s KN026 Trial Achieves Key Milestone

Alphamab Oncology ( (HK:9966) ) just unveiled an update.

Alphamab Oncology announced that its pivotal Phase II/III clinical trial of KN026, a next-generation HER2-targeted therapy, has met its primary endpoint of progression-free survival (PFS) in patients with HER2-positive gastric cancer. The trial results indicate a significant improvement in PFS when KN026 is combined with chemotherapy, suggesting potential benefits over current standard treatments. This advancement could enhance Alphamab’s position in the oncology market and provide new treatment options for patients with advanced cancer.

More about Alphamab Oncology

Alphamab Oncology is a leading biopharmaceutical company in China, specializing in antibody-drug conjugates (ADCs), bispecific antibodies, and multifunctional protein engineering. The company has a robust pipeline of oncology treatments, including products in various stages of clinical trials, and leverages proprietary technology platforms to develop innovative therapies.

YTD Price Performance: 94.86%

Average Trading Volume: 5,414,430

Technical Sentiment Signal: Sell

Current Market Cap: HK$6.58B

For an in-depth examination of 9966 stock, go to TipRanks’ Stock Analysis page.